tickerreport.com
Positivewww.tickerreport.com ·
Edgewise Therapeutics Nasdaqewtx Announces Quarterly Earnings Results
InsidersStewardGlomerulosclerosisAnalysts
Topic context
This topic has been covered 293756 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEarnings beat but insider selling and stock decline suggest weak commercial confidence. No direct product/commodity price impact; channel is equity sentiment for a single biotech firm. Impact is company-specific, not sector-wide.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Edgewise Therapeutics reported Q1 2026 EPS loss of $0.46, beating consensus by $0.04.
- Stock fell 0.7% to $35.32 on 1,015,652 shares traded.
- CMO Joanne M. Donovan sold 50,000 shares for ~$1.93 million.
- Analyst price targets range $32-$46, consensus $39.67.
- Company focuses on precision medicines for rare kidney and neuromuscular diseases.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
economictimes.indiatimes.com